« Back
Home /
Fenebrutinib

Fenebrutinib

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	100 mg
Item no.	HY-19834-100mg
Targets	BTK
CASRN	1434048-34-6
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research[1].
StorageTemperature	4°C (Powder, stored under nitrogen)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	664.80
Clinical_Information	Phase 3
Manufacturers Research_Area	Cancer
Solubility	DMSO : ≥ 23 mg/mL
Pathway	Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19834-100mg-safety-datasheet.pdf